Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

详细信息    查看全文

• 作者：Satoshi Ikeda ; Akimasa Sekine ; Tomohisa Baba ; Hideaki Yamakawa…
• 关键词：Idiopathic pulmonary fibrosis ; Acute exacerbation ; Nintedanib
• 刊名：BMC Pulmonary Medicine
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：1,320 KB
• 刊物主题：Pneumology/Respiratory System; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2466

文摘

Background Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC). Although the INPULSIS™ trials indicate that nintedanib may serve to prevent acute exacerbations or delay the time to the first acute exacerbation, a certain number of IPF patients develop acute exacerbations while receiving nintedanib. However, there has been no report on the readministration of nintedanib in IPF patients who develop acute exacerbations during initial treatment with nintedanib.